Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Action of PRFM for Skin Volume Augmentation
NCT00956020Phase 2Completed
- Sponsor
- New York Eye and Ear Infirmary of Mount Sinai
- Start
- Oct 2009
- Primary completion
- Feb 2011
- Modality
- Hydrogel Systems, Recombinant Proteins and Enzymes, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of platelet-rich fibrin matrix in Skin aging, sponsored by New York Eye and Ear Infirmary of Mount Sinai. Primary endpoints: Qualitative Changes in Dermal and Sub Dermal Collagen and Cellularity at 12 weeks and Qualitative Changes in Dermal and Sub Dermal Vascularity at 12 weeks. Started Oct 2009; status: completed.
02
Drugs
platelet-rich fibrin matrix
03
Conditions
Skin aging
Beyond the preview
Go deeper on NCT00956020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00956020.